2021. Phase II trial of humanized anti-Lewis Y monoclonal antibody for advanced hormone receptor-positive breast cancer that progressed following endocrine therapy. Clinics. 76, (Oct. 2021), e3146. DOI:https://doi.org/10.6061/clinics/2021/e3146.